We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Reported revenues of $6.5 million in 1Q24, up 116% compared to 1Q23 Reported gross margin of 85% in 1Q24 Secured up to $50 million of debt financing with OrbiMed to support TriNav® Infusion...
– Accomplished industry veteran brings deep strategic and operational expertise TriSalus Life Sciences® Inc. (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with...
Call Scheduled for Wednesday, May 15, 2024, at 9:00 a.m. ET TriSalus Life Sciences® Inc., (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with immunotherapy to...
$25 million funded at close; up to $25 million of additional capital available at the Company’s option, based on the achievement of certain revenue thresholds Capital from the transaction is...
Reported revenues of $5.7 million in 4Q23, up 77% over prior year Full year revenues of $18.5 million, up 49% over prior year Gross Margin of 90% in 4Q23 and 86% for full year CMS reimbursement...
– New safety and feasibility data from Phase 1/1b PERIO-03 trial for locally advanced pancreatic cancer supports further development of the novel TriSalus Infusion System for therapeutic delivery...
TriSalus Life Sciences® Inc. (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors...
– Q4 sales of approximately $5.7 million represent 77% growth versus 2022 – – Q4 and full year gross margin of approximately 90% and 86% respectively – – Full year 2024 sales growth expected to...
– Nelitolimod, a class C TLR-9 agonist formerly called SD-101, is the Company’s therapeutic candidate designed to overcome biologic barriers in liver and pancreatic tumors – Nelitolimod is...
– Data published in Current Medical Research and Opinion provide a comparison of the TriNav Infusion System vs. standard drug delivery and show the ability of TriNav to successfully treat sicker...
| Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.27 | -2.63671875 | 10.24 | 10.24 | 9.3 | 18887 | 9.71805045 | CS |
| 4 | -0.03 | -0.3 | 10 | 10.24 | 9.11 | 50949 | 9.68076831 | CS |
| 12 | 0.77 | 8.36956521739 | 9.2 | 10.42 | 8.59 | 42543 | 9.57614528 | CS |
| 26 | 6.4 | 179.271708683 | 3.57 | 10.42 | 3.32 | 56527 | 8.25407415 | CS |
| 52 | -3.83 | -27.7536231884 | 13.8 | 16.24 | 3.32 | 52107 | 7.53382838 | CS |
| 156 | -3.83 | -27.7536231884 | 13.8 | 16.24 | 3.32 | 52107 | 7.53382838 | CS |
| 260 | -3.83 | -27.7536231884 | 13.8 | 16.24 | 3.32 | 52107 | 7.53382838 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
